Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 1,001–1,050 of 1,446 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT00354107	Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent…	Phase 1 / Phase 2	terminated	Jul 20, 2006	National Cancer Institute (NCI)	not stated	Not stated
NCT02366663	BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL(SPINOZA)	Phase 3	terminated	Feb 19, 2015	City of Hope Medical Center	Withdrawal of sponsor support	Other (stated, no rule matched)
NCT01313611	BRIEF Bendamustine and Rituximab In Elderly Follicular(BRIEF)	Phase 2	terminated	Mar 14, 2011	The Lymphoma Academic Research Organisation	Treament with rituximab during maintenance phase was stoped, according to DSMC recommendations,…	Other (stated, no rule matched)
NCT01147393	Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular…	Phase 1 / Phase 2	terminated	Jun 22, 2010	Weill Medical College of Cornell University	closed to enrollment due to slow patient accrual	Enrollment / accrual
NCT00588263	Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish…	—	withdrawn	Jan 8, 2008	Memorial Sloan Kettering Cancer Center	Data from MSK-IMPACT is sufficient for relevant analyses going forward	Other (stated, no rule matched)
NCT02578511	Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With…	Phase 1	withdrawn	Oct 19, 2015	Ehab L Atallah	No enrollment, another competing study and difficult to find the right person to enroll on this…	Enrollment / accrual
NCT00481832	Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's…	Phase 2	terminated	Jun 4, 2007	Stanford University	Accrual Factor	Enrollment / accrual
NCT01002248	Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple…	Phase 3	terminated	Oct 27, 2009	AEterna Zentaris	not stated	Not stated
NCT01315873	Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma	Phase 2	terminated	Mar 15, 2011	NYU Langone Health	PI left the institution before all data analysis was completed	Investigator
NCT00003500	Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV…	Phase 2	terminated	Jan 27, 2003	Burzynski Research Institute	slow accrual	Enrollment / accrual
NCT00003501	Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV…	Phase 2	terminated	Jan 27, 2003	Burzynski Research Institute	slow accrual	Enrollment / accrual
NCT00003512	Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's…	Phase 2	withdrawn	Jan 27, 2003	Burzynski Research Institute	No participants enrolled	Enrollment / accrual
NCT01675141	Lenalidomide Maintenance Therapy for Multiple Myeloma	Phase 2	terminated	Aug 29, 2012	National Cancer Institute (NCI)	Original investigator left the NIH and the primary outcome was not reached	Investigator
NCT01446900	R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia…	Phase 2	terminated	Oct 5, 2011	European Institute of Oncology	low rate in patient accrual	Enrollment / accrual
NCT02983097	Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa,…(R²-DHAP)	Phase 1 / Phase 2	terminated	Dec 6, 2016	Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH	Phase II: no scientific interests are given anymore	Other (stated, no rule matched)
NCT00455897	CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large…	Phase 2	terminated	Apr 4, 2007	Massachusetts General Hospital	Accrual was too slow. Trial terminated	Enrollment / accrual
NCT01929941	An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced…	Phase 1	terminated	Aug 28, 2013	Incyte Corporation	Business decision.	Sponsor / business decision
NCT03205891	Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin…	Phase 1	withdrawn	Jul 2, 2017	M.D. Anderson Cancer Center	Change in treatment priorities for these disease types as well as staffing concerns.	Other (stated, no rule matched)
NCT02200848	Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic…	Phase 1	terminated	Jul 25, 2014	Georgetown University	Recruitment difficulties and toxicity	Safety / toxicity
NCT02456675	INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory…	Phase 2	terminated	May 28, 2015	Incyte Corporation	A decision was made to terminate the study due to the changing treatment landscape for the…	Other (stated, no rule matched)
NCT00562965	Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined…	Phase 3	terminated	Nov 26, 2007	Pfizer	See termination reason in detailed description.	Other (stated, no rule matched)
NCT01564277	Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies	Phase 2	terminated	Mar 27, 2012	Roswell Park Cancer Institute	low accrual	Enrollment / accrual
NCT01332617	Phase II Study of Simvastatin for Relapsed/Refractory Myeloma	Phase 2	withdrawn	Apr 11, 2011	University of Louisville	Investigators no longer interested in activating study	Other (stated, no rule matched)
NCT00963872	Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and…	Phase 1 / Phase 2	terminated	Aug 24, 2009	Masonic Cancer Center, University of Minnesota	Lack of efficacy after interim analysis	Efficacy / futility
NCT01636388	Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus…	Phase 2	terminated	Jul 10, 2012	New York Medical College	funding ended	Funding
NCT02875002	Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive…	Phase 1	withdrawn	Aug 22, 2016	Yale University	not stated	Not stated
NCT03100877	Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating…	Phase 1 / Phase 2	withdrawn	Apr 4, 2017	City of Hope Medical Center	Feasibility Issues	Other (stated, no rule matched)
NCT00772668	Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL…	N/A	terminated	Oct 15, 2008	University of Miami	Funding	Funding
NCT02229981	Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large…(ABC-102)	Phase 1 / Phase 2	withdrawn	Sep 3, 2014	RedHill Biopharma Limited	Study was discontinued due to lack of recruitment.	Enrollment / accrual
NCT01343368	Preservation of Ovarian Function After Hematopoietic Cell Transplant	Phase 2	terminated	Apr 28, 2011	Masonic Cancer Center, University of Minnesota	not stated	Not stated
NCT01163201	T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in…	Phase 1 / Phase 2	withdrawn	Jul 15, 2010	Masonic Cancer Center, University of Minnesota	Replaced by a new study	Other (stated, no rule matched)
NCT01518465	Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously…	Phase 2	terminated	Jan 26, 2012	University of Southern California	Insufficient Accrual	Enrollment / accrual
NCT01969565	Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed…	Phase 2	terminated	Oct 25, 2013	Emory University	Logistical reasons	Other (stated, no rule matched)
NCT00574080	UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide	Phase 3	terminated	Dec 14, 2007	University of Arkansas	low accrual	Enrollment / accrual
NCT00657553	Preemptive Strike With Bortezomib in Multiple Myeloma Patients(2007-77)	Phase 3	terminated	Apr 14, 2008	University of Arkansas	Due to poor accrual	Enrollment / accrual
NCT01187446	Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides	Phase 1 / Phase 2	terminated	Aug 24, 2010	Stanford University	Business decision by funding source	Funding
NCT02700022	A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell…	Phase 1	terminated	Mar 7, 2016	UNC Lineberger Comprehensive Cancer Center	Lack of funding	Funding
NCT02815397	DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma(DLBCL)	Phase 2	terminated	Jun 28, 2016	Rush University Medical Center	Poor accrual	Enrollment / accrual
NCT00722865	Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for…	Phase 2	terminated	Jul 28, 2008	Massachusetts General Hospital	slow enrollment	Enrollment / accrual
NCT00113919	UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma…	Phase 1 / Phase 2	terminated	Jun 13, 2005	University of Arkansas	Due to poor accrual	Enrollment / accrual
NCT01646762	Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed…	Phase 2	terminated	Jul 20, 2012	Mayo Clinic	Did not pass the Stage 1 interim analysis.	Efficacy / futility
NCT02455297	Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)	Phase 2	terminated	May 27, 2015	Bayer	not stated	Not stated
NCT01251172	RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma	Phase 2	withdrawn	Dec 1, 2010	National Cancer Institute (NCI)	Lack of Drug Supply	Drug supply
NCT02662296	Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic…	Phase 2	withdrawn	Jan 25, 2016	Fred Hutchinson Cancer Center	Low enrollment	Enrollment / accrual
NCT03283046	Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly…	Phase 1	withdrawn	Sep 14, 2017	M.D. Anderson Cancer Center	Similar to another study.	Other (stated, no rule matched)
NCT00837174	Relapsed and/or Refractory Non-Hodgkin Lymphoma Study(COMBOSTAT)	Phase 2	withdrawn	Feb 5, 2009	The Methodist Hospital Research Institute	Study never activated/opened as funding source and other support not available.	Funding
NCT00849251	Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and…	Phase 1 / Phase 2	terminated	Feb 23, 2009	University of Washington	One of the study drugs is not available.	Other (stated, no rule matched)
NCT00857324	Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple…	Phase 1 / Phase 2	terminated	Mar 6, 2009	Tiziana Marangon	The Phase I of the study was completed, but Phase 2 has not been activated	Other (stated, no rule matched)
NCT02677948	Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic…	Phase 1 / Phase 2	withdrawn	Feb 9, 2016	University of Michigan Rogel Cancer Center	FDA has placed all trials involving Pacritinib on Full Clinical Hold	Other (stated, no rule matched)
NCT01720043	Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients	Phase 2	terminated	Nov 1, 2012	University of Utah	Slow Accrual	Enrollment / accrual

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 24 days agoSource updated Mar 14, 2018source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules